Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,735
archived clinical trials in
Psoriasis

Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis
Status: Enrolling
Updated:  3/18/2016
Virginia Clinical Research, Inc.
mi
from
Norfolk, VA
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis
Status: Enrolling
Updated: 3/18/2016
Virginia Clinical Research, Inc.
mi
from
Norfolk, VA
Click here to add this to my saved trials
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis
Status: Enrolling
Updated:  3/18/2016
University of California Irvine-Department of Dermatology
mi
from
Irvine, CA
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis
Status: Enrolling
Updated: 3/18/2016
University of California Irvine-Department of Dermatology
mi
from
Irvine, CA
Click here to add this to my saved trials
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis
Status: Enrolling
Updated:  3/18/2016
University of California, San Diego
mi
from
San Diego, CA
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis
Status: Enrolling
Updated: 3/18/2016
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis
Status: Enrolling
Updated:  3/18/2016
George Washington University
mi
from
Washington,
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis
Status: Enrolling
Updated: 3/18/2016
George Washington University
mi
from
Washington,
Click here to add this to my saved trials
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis
Status: Enrolling
Updated:  3/18/2016
Florida Center for Dermatology, P.A
mi
from
Jacksonville, FL
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis
Status: Enrolling
Updated: 3/18/2016
Florida Center for Dermatology, P.A
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis
Status: Enrolling
Updated:  3/18/2016
NorthShore University HealthSystem
mi
from
Skokie, IL
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis
Status: Enrolling
Updated: 3/18/2016
NorthShore University HealthSystem
mi
from
Skokie, IL
Click here to add this to my saved trials
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis
Status: Enrolling
Updated:  3/18/2016
Southern Illinois University School of Medicine
mi
from
Springfield, IL
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis
Status: Enrolling
Updated: 3/18/2016
Southern Illinois University School of Medicine
mi
from
Springfield, IL
Click here to add this to my saved trials
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis
Status: Enrolling
Updated:  3/18/2016
Robert Wood Johnson Medical School
mi
from
Somerset, NJ
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis
Status: Enrolling
Updated: 3/18/2016
Robert Wood Johnson Medical School
mi
from
Somerset, NJ
Click here to add this to my saved trials
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis
Status: Enrolling
Updated:  3/18/2016
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis
Status: Enrolling
Updated: 3/18/2016
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis
Status: Enrolling
Updated:  3/18/2016
Ohio State University Medical Center
mi
from
Columbus, OH
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis
Status: Enrolling
Updated: 3/18/2016
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis
Status: Enrolling
Updated:  3/18/2016
University of Pittsburgh Medical Center
mi
from
Pittsburg, PA
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis
Status: Enrolling
Updated: 3/18/2016
University of Pittsburgh Medical Center
mi
from
Pittsburg, PA
Click here to add this to my saved trials
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis
Status: Enrolling
Updated:  3/18/2016
Tennesse Clinical Research Center
mi
from
Nashville, TN
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis
Status: Enrolling
Updated: 3/18/2016
Tennesse Clinical Research Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis
Status: Enrolling
Updated:  3/18/2016
Dermatology Associates of Seattle
mi
from
Seattle, WA
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis
Status: Enrolling
Updated: 3/18/2016
Dermatology Associates of Seattle
mi
from
Seattle, WA
Click here to add this to my saved trials
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis
Status: Enrolling
Updated:  3/18/2016
The Skin Centre
mi
from
Benowa,
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis
Status: Enrolling
Updated: 3/18/2016
The Skin Centre
mi
from
Benowa,
Click here to add this to my saved trials
Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study
Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study
Status: Enrolling
Updated:  3/22/2016
Massachusetts General Hospital
mi
from
Boston, MA
Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study
Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study
Status: Enrolling
Updated: 3/22/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Golimumab Safety and Surveillance Program Using the Ingenix NHI Database
A Large US Health Insurance Claims Database Will be Used to Estimate the Incidence of Serious Outcomes in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis Treated With Golimumab and Other Types of Biological and Systemic Non Biological Treatments
Status: Enrolling
Updated:  3/24/2016
OptumInsight Life Sciences
mi
from
Waltham, MA
Golimumab Safety and Surveillance Program Using the Ingenix NHI Database
A Large US Health Insurance Claims Database Will be Used to Estimate the Incidence of Serious Outcomes in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis Treated With Golimumab and Other Types of Biological and Systemic Non Biological Treatments
Status: Enrolling
Updated: 3/24/2016
OptumInsight Life Sciences
mi
from
Waltham, MA
Click here to add this to my saved trials
Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis
A Phase 1, Multicenter, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated:  3/29/2016
PPD Development, LP
mi
from
Austin, TX
Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis
A Phase 1, Multicenter, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated: 3/29/2016
PPD Development, LP
mi
from
Austin, TX
Click here to add this to my saved trials
Use of Botulinum Toxin to Treat Psoriasis
Pilot Study on the Safety and Efficacy of Botulinum Toxin Injections in the Treatment of Psoriasis Vulgaris.
Status: Enrolling
Updated:  3/31/2016
Univerisity of Minnesota
mi
from
Minneapolis, MN
Use of Botulinum Toxin to Treat Psoriasis
Pilot Study on the Safety and Efficacy of Botulinum Toxin Injections in the Treatment of Psoriasis Vulgaris.
Status: Enrolling
Updated: 3/31/2016
Univerisity of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
Pharmacokinetics and Pharmacodynamics of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 14 Days Under Conditions of Maximal Use in Pediatric Subjects (2 to 12 Years of Age) With Plaque Psoriasis
Status: Enrolling
Updated:  4/5/2016
Rady Children's Hospital - Pediatric and Adolescent Dermatology
mi
from
San Diego, CA
PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
Pharmacokinetics and Pharmacodynamics of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 14 Days Under Conditions of Maximal Use in Pediatric Subjects (2 to 12 Years of Age) With Plaque Psoriasis
Status: Enrolling
Updated: 4/5/2016
Rady Children's Hospital - Pediatric and Adolescent Dermatology
mi
from
San Diego, CA
Click here to add this to my saved trials
PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
Pharmacokinetics and Pharmacodynamics of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 14 Days Under Conditions of Maximal Use in Pediatric Subjects (2 to 12 Years of Age) With Plaque Psoriasis
Status: Enrolling
Updated:  4/5/2016
Dawes Fretzin Clinical Research Group, LLC
mi
from
Indianapolis, IN
PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
Pharmacokinetics and Pharmacodynamics of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 14 Days Under Conditions of Maximal Use in Pediatric Subjects (2 to 12 Years of Age) With Plaque Psoriasis
Status: Enrolling
Updated: 4/5/2016
Dawes Fretzin Clinical Research Group, LLC
mi
from
Indianapolis, IN
Click here to add this to my saved trials
PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
Pharmacokinetics and Pharmacodynamics of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 14 Days Under Conditions of Maximal Use in Pediatric Subjects (2 to 12 Years of Age) With Plaque Psoriasis
Status: Enrolling
Updated:  4/5/2016
University of Michigan Medical Center
mi
from
Ann Arbor, MI
PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
Pharmacokinetics and Pharmacodynamics of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 14 Days Under Conditions of Maximal Use in Pediatric Subjects (2 to 12 Years of Age) With Plaque Psoriasis
Status: Enrolling
Updated: 4/5/2016
University of Michigan Medical Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
Pharmacokinetics and Pharmacodynamics of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 14 Days Under Conditions of Maximal Use in Pediatric Subjects (2 to 12 Years of Age) With Plaque Psoriasis
Status: Enrolling
Updated:  4/5/2016
University of North Carolina Dermatology and Skin Cancer Center
mi
from
Chapel Hill, NC
PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
Pharmacokinetics and Pharmacodynamics of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 14 Days Under Conditions of Maximal Use in Pediatric Subjects (2 to 12 Years of Age) With Plaque Psoriasis
Status: Enrolling
Updated: 4/5/2016
University of North Carolina Dermatology and Skin Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
Pharmacokinetics and Pharmacodynamics of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 14 Days Under Conditions of Maximal Use in Pediatric Subjects (2 to 12 Years of Age) With Plaque Psoriasis
Status: Enrolling
Updated:  4/5/2016
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
Pharmacokinetics and Pharmacodynamics of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 14 Days Under Conditions of Maximal Use in Pediatric Subjects (2 to 12 Years of Age) With Plaque Psoriasis
Status: Enrolling
Updated: 4/5/2016
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
Pharmacokinetics and Pharmacodynamics of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 14 Days Under Conditions of Maximal Use in Pediatric Subjects (2 to 12 Years of Age) With Plaque Psoriasis
Status: Enrolling
Updated:  4/5/2016
Menter Dermatology Research Institute
mi
from
Dallas, TX
PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
Pharmacokinetics and Pharmacodynamics of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 14 Days Under Conditions of Maximal Use in Pediatric Subjects (2 to 12 Years of Age) With Plaque Psoriasis
Status: Enrolling
Updated: 4/5/2016
Menter Dermatology Research Institute
mi
from
Dallas, TX
Click here to add this to my saved trials
PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
Pharmacokinetics and Pharmacodynamics of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 14 Days Under Conditions of Maximal Use in Pediatric Subjects (2 to 12 Years of Age) With Plaque Psoriasis
Status: Enrolling
Updated:  4/5/2016
Clinical Trials of Texas, Inc.
mi
from
San Antonio, TX
PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
Pharmacokinetics and Pharmacodynamics of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 14 Days Under Conditions of Maximal Use in Pediatric Subjects (2 to 12 Years of Age) With Plaque Psoriasis
Status: Enrolling
Updated: 4/5/2016
Clinical Trials of Texas, Inc.
mi
from
San Antonio, TX
Click here to add this to my saved trials
PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
Pharmacokinetics and Pharmacodynamics of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 14 Days Under Conditions of Maximal Use in Pediatric Subjects (2 to 12 Years of Age) With Plaque Psoriasis
Status: Enrolling
Updated:  4/5/2016
Seattle Children's Hospital
mi
from
Seattle, WA
PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
Pharmacokinetics and Pharmacodynamics of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 14 Days Under Conditions of Maximal Use in Pediatric Subjects (2 to 12 Years of Age) With Plaque Psoriasis
Status: Enrolling
Updated: 4/5/2016
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Plaque Psoriasis Study in Pediatric Subjects
A Multicenter, Randomized, Double Blind, Parallel Group, Vehicle Controlled, Study of the Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 8 Weeks in Pediatric Subjects (2 to 12 Years of Age) With Mild to Moderate Plaque Psoriasis
Status: Enrolling
Updated:  4/5/2016
David Stoll, MD
mi
from
Beverly Hills, CA
Plaque Psoriasis Study in Pediatric Subjects
A Multicenter, Randomized, Double Blind, Parallel Group, Vehicle Controlled, Study of the Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 8 Weeks in Pediatric Subjects (2 to 12 Years of Age) With Mild to Moderate Plaque Psoriasis
Status: Enrolling
Updated: 4/5/2016
David Stoll, MD
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Plaque Psoriasis Study in Pediatric Subjects
A Multicenter, Randomized, Double Blind, Parallel Group, Vehicle Controlled, Study of the Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 8 Weeks in Pediatric Subjects (2 to 12 Years of Age) With Mild to Moderate Plaque Psoriasis
Status: Enrolling
Updated:  4/5/2016
Center for Dermatology & Laser Surgery
mi
from
Sacramento, CA
Plaque Psoriasis Study in Pediatric Subjects
A Multicenter, Randomized, Double Blind, Parallel Group, Vehicle Controlled, Study of the Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 8 Weeks in Pediatric Subjects (2 to 12 Years of Age) With Mild to Moderate Plaque Psoriasis
Status: Enrolling
Updated: 4/5/2016
Center for Dermatology & Laser Surgery
mi
from
Sacramento, CA
Click here to add this to my saved trials
Plaque Psoriasis Study in Pediatric Subjects
A Multicenter, Randomized, Double Blind, Parallel Group, Vehicle Controlled, Study of the Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 8 Weeks in Pediatric Subjects (2 to 12 Years of Age) With Mild to Moderate Plaque Psoriasis
Status: Enrolling
Updated:  4/5/2016
Dermatology Specialists Research
mi
from
Louisville, KY
Plaque Psoriasis Study in Pediatric Subjects
A Multicenter, Randomized, Double Blind, Parallel Group, Vehicle Controlled, Study of the Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 8 Weeks in Pediatric Subjects (2 to 12 Years of Age) With Mild to Moderate Plaque Psoriasis
Status: Enrolling
Updated: 4/5/2016
Dermatology Specialists Research
mi
from
Louisville, KY
Click here to add this to my saved trials
Plaque Psoriasis Study in Pediatric Subjects
A Multicenter, Randomized, Double Blind, Parallel Group, Vehicle Controlled, Study of the Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 8 Weeks in Pediatric Subjects (2 to 12 Years of Age) With Mild to Moderate Plaque Psoriasis
Status: Enrolling
Updated:  4/5/2016
University of Mississippi Medical Center
mi
from
Jackson, MS
Plaque Psoriasis Study in Pediatric Subjects
A Multicenter, Randomized, Double Blind, Parallel Group, Vehicle Controlled, Study of the Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 8 Weeks in Pediatric Subjects (2 to 12 Years of Age) With Mild to Moderate Plaque Psoriasis
Status: Enrolling
Updated: 4/5/2016
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
Plaque Psoriasis Study in Pediatric Subjects
A Multicenter, Randomized, Double Blind, Parallel Group, Vehicle Controlled, Study of the Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 8 Weeks in Pediatric Subjects (2 to 12 Years of Age) With Mild to Moderate Plaque Psoriasis
Status: Enrolling
Updated:  4/5/2016
Montefiore Medical Center
mi
from
Bronx, NY
Plaque Psoriasis Study in Pediatric Subjects
A Multicenter, Randomized, Double Blind, Parallel Group, Vehicle Controlled, Study of the Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 8 Weeks in Pediatric Subjects (2 to 12 Years of Age) With Mild to Moderate Plaque Psoriasis
Status: Enrolling
Updated: 4/5/2016
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Plaque Psoriasis Study in Pediatric Subjects
A Multicenter, Randomized, Double Blind, Parallel Group, Vehicle Controlled, Study of the Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 8 Weeks in Pediatric Subjects (2 to 12 Years of Age) With Mild to Moderate Plaque Psoriasis
Status: Enrolling
Updated:  4/5/2016
RCMC Center for Dermatology at Linden Oaks
mi
from
Rochester, NY
Plaque Psoriasis Study in Pediatric Subjects
A Multicenter, Randomized, Double Blind, Parallel Group, Vehicle Controlled, Study of the Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 8 Weeks in Pediatric Subjects (2 to 12 Years of Age) With Mild to Moderate Plaque Psoriasis
Status: Enrolling
Updated: 4/5/2016
RCMC Center for Dermatology at Linden Oaks
mi
from
Rochester, NY
Click here to add this to my saved trials
Plaque Psoriasis Study in Pediatric Subjects
A Multicenter, Randomized, Double Blind, Parallel Group, Vehicle Controlled, Study of the Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 8 Weeks in Pediatric Subjects (2 to 12 Years of Age) With Mild to Moderate Plaque Psoriasis
Status: Enrolling
Updated:  4/5/2016
Clinical Partners, LLC
mi
from
Johnston, RI
Plaque Psoriasis Study in Pediatric Subjects
A Multicenter, Randomized, Double Blind, Parallel Group, Vehicle Controlled, Study of the Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 8 Weeks in Pediatric Subjects (2 to 12 Years of Age) With Mild to Moderate Plaque Psoriasis
Status: Enrolling
Updated: 4/5/2016
Clinical Partners, LLC
mi
from
Johnston, RI
Click here to add this to my saved trials
Plaque Psoriasis Study in Pediatric Subjects
A Multicenter, Randomized, Double Blind, Parallel Group, Vehicle Controlled, Study of the Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 8 Weeks in Pediatric Subjects (2 to 12 Years of Age) With Mild to Moderate Plaque Psoriasis
Status: Enrolling
Updated:  4/5/2016
Dermatology and Laser Center of Charleston
mi
from
Charleston, SC
Plaque Psoriasis Study in Pediatric Subjects
A Multicenter, Randomized, Double Blind, Parallel Group, Vehicle Controlled, Study of the Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 8 Weeks in Pediatric Subjects (2 to 12 Years of Age) With Mild to Moderate Plaque Psoriasis
Status: Enrolling
Updated: 4/5/2016
Dermatology and Laser Center of Charleston
mi
from
Charleston, SC
Click here to add this to my saved trials
Plaque Psoriasis Study in Pediatric Subjects
A Multicenter, Randomized, Double Blind, Parallel Group, Vehicle Controlled, Study of the Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 8 Weeks in Pediatric Subjects (2 to 12 Years of Age) With Mild to Moderate Plaque Psoriasis
Status: Enrolling
Updated:  4/5/2016
DermResearch, Inc.
mi
from
Austin, TX
Plaque Psoriasis Study in Pediatric Subjects
A Multicenter, Randomized, Double Blind, Parallel Group, Vehicle Controlled, Study of the Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 8 Weeks in Pediatric Subjects (2 to 12 Years of Age) With Mild to Moderate Plaque Psoriasis
Status: Enrolling
Updated: 4/5/2016
DermResearch, Inc.
mi
from
Austin, TX
Click here to add this to my saved trials
Plaque Psoriasis Study in Pediatric Subjects
A Multicenter, Randomized, Double Blind, Parallel Group, Vehicle Controlled, Study of the Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 8 Weeks in Pediatric Subjects (2 to 12 Years of Age) With Mild to Moderate Plaque Psoriasis
Status: Enrolling
Updated:  4/5/2016
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Plaque Psoriasis Study in Pediatric Subjects
A Multicenter, Randomized, Double Blind, Parallel Group, Vehicle Controlled, Study of the Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 8 Weeks in Pediatric Subjects (2 to 12 Years of Age) With Mild to Moderate Plaque Psoriasis
Status: Enrolling
Updated: 4/5/2016
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Plaque Psoriasis Study in Pediatric Subjects
A Multicenter, Randomized, Double Blind, Parallel Group, Vehicle Controlled, Study of the Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 8 Weeks in Pediatric Subjects (2 to 12 Years of Age) With Mild to Moderate Plaque Psoriasis
Status: Enrolling
Updated:  4/5/2016
Clinical Trials of Texas, Inc.
mi
from
San Antonio, TX
Plaque Psoriasis Study in Pediatric Subjects
A Multicenter, Randomized, Double Blind, Parallel Group, Vehicle Controlled, Study of the Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 8 Weeks in Pediatric Subjects (2 to 12 Years of Age) With Mild to Moderate Plaque Psoriasis
Status: Enrolling
Updated: 4/5/2016
Clinical Trials of Texas, Inc.
mi
from
San Antonio, TX
Click here to add this to my saved trials
Plaque Psoriasis Study in Pediatric Subjects
A Multicenter, Randomized, Double Blind, Parallel Group, Vehicle Controlled, Study of the Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 8 Weeks in Pediatric Subjects (2 to 12 Years of Age) With Mild to Moderate Plaque Psoriasis
Status: Enrolling
Updated:  4/5/2016
Jordan Valley Dermatology
mi
from
West Jordan, UT
Plaque Psoriasis Study in Pediatric Subjects
A Multicenter, Randomized, Double Blind, Parallel Group, Vehicle Controlled, Study of the Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 8 Weeks in Pediatric Subjects (2 to 12 Years of Age) With Mild to Moderate Plaque Psoriasis
Status: Enrolling
Updated: 4/5/2016
Jordan Valley Dermatology
mi
from
West Jordan, UT
Click here to add this to my saved trials
Plaque Psoriasis Study in Pediatric Subjects
A Multicenter, Randomized, Double Blind, Parallel Group, Vehicle Controlled, Study of the Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 8 Weeks in Pediatric Subjects (2 to 12 Years of Age) With Mild to Moderate Plaque Psoriasis
Status: Enrolling
Updated:  4/5/2016
UCL Saint Luc
mi
from
Brussel,
Plaque Psoriasis Study in Pediatric Subjects
A Multicenter, Randomized, Double Blind, Parallel Group, Vehicle Controlled, Study of the Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 8 Weeks in Pediatric Subjects (2 to 12 Years of Age) With Mild to Moderate Plaque Psoriasis
Status: Enrolling
Updated: 4/5/2016
UCL Saint Luc
mi
from
Brussel,
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
Rheumatology Associates, PC
mi
from
Birmingham, AL
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
Rheumatology Associates, PC
mi
from
Birmingham, AL
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
Rheumatology Associates Of North Alabama, P.C.
mi
from
Huntsville, AL
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
Rheumatology Associates Of North Alabama, P.C.
mi
from
Huntsville, AL
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
Medvin Clinical Research
mi
from
Covina, CA
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
Medvin Clinical Research
mi
from
Covina, CA
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
Desert Medical Advances
mi
from
Palm Desert, CA
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
Desert Medical Advances
mi
from
Palm Desert, CA
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
San Diego Arthritis Medical Clinic
mi
from
San Diego, CA
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
San Diego Arthritis Medical Clinic
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
Millennium Research
mi
from
Ormond Beach, FL
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
Millennium Research
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
The Arthritis Center
mi
from
Palm Harbor, FL
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
The Arthritis Center
mi
from
Palm Harbor, FL
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
Klein & Associates MD, PA.
mi
from
Hagerstown, MD
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
Klein & Associates MD, PA.
mi
from
Hagerstown, MD
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
Clinical Pharmacology Study Group
mi
from
Worcester, MA
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
Clinical Pharmacology Study Group
mi
from
Worcester, MA
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
St. Paul Rheumatology, PA
mi
from
Eagan, MN
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
St. Paul Rheumatology, PA
mi
from
Eagan, MN
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
Physician Research Collaboration
mi
from
Lincoln, NE
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
Physician Research Collaboration
mi
from
Lincoln, NE
Click here to add this to my saved trials